NEW YORK (GenomeWeb News) – Trovagene and US Oncology Research today announced a deal for the use of Trovagene's technology to determine whether KRAS mutations can be evaluated in urine to monitor pancreatic cancer patients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.